| scholarly article | Q13442814 |
| P50 | author | Valeria Sordi | Q42571239 |
| Lorenzo Piemonti | Q37382584 | ||
| Aldo Scarpa | Q37392347 | ||
| P2093 | author name string | M Reni | |
| V Di Carlo | |||
| M Dandrea | |||
| S Beghelli | |||
| A Mercalli | |||
| R Formicola | |||
| P2860 | cites work | A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 |
| 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer | Q28359288 | ||
| The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). | Q40713819 | ||
| Clinical pharmacokinetics of irinotecan | Q40880283 | ||
| Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. | Q40925904 | ||
| Chemotherapy of adenocarcinoma of the pancreas | Q40982493 | ||
| Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis | Q41140052 | ||
| Gemcitabine: a cytidine analogue active against solid tumors | Q41444053 | ||
| Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer | Q43533552 | ||
| Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial | Q43693195 | ||
| Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines | Q43740871 | ||
| In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. | Q43860653 | ||
| Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic | Q43991263 | ||
| A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. | Q44104072 | ||
| Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q44567807 | ||
| Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma | Q44955215 | ||
| Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer | Q45148156 | ||
| A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors | Q45309585 | ||
| Treatment of pancreatic cancer: challenge of the facts | Q47680946 | ||
| Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. | Q53507125 | ||
| Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients | Q59358914 | ||
| Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors | Q71059776 | ||
| Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion | Q72211760 | ||
| Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion | Q72217954 | ||
| Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study | Q72327076 | ||
| Phase I and pharmacokinetic trial of weekly CPT-11 | Q72576855 | ||
| Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design | Q72732581 | ||
| LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes | Q73148807 | ||
| Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells | Q73273788 | ||
| Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors | Q73675198 | ||
| Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer | Q73814763 | ||
| Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma | Q78125056 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer | Q30438645 | ||
| Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer | Q33331583 | ||
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer | Q33360410 | ||
| Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial | Q33364008 | ||
| Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial | Q33366562 | ||
| Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer | Q33367600 | ||
| A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer | Q33367733 | ||
| Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. | Q33370390 | ||
| A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin | Q33397033 | ||
| Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients | Q33502692 | ||
| An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma | Q33585599 | ||
| Overview of phase I trials of multitargeted antifolate (MTA, LY231514). | Q33794743 | ||
| Overview of phase II trials of MTA in solid tumors | Q33794749 | ||
| T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma | Q33857087 | ||
| Basis for effective combination cancer chemotherapy with antimetabolites | Q33919546 | ||
| Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies | Q34086049 | ||
| New chemotherapy approaches in colorectal cancer | Q34295174 | ||
| Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. | Q34525788 | ||
| Second-line treatment of ovarian cancer with single-agent gemcitabine | Q34526669 | ||
| Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate | Q34550827 | ||
| The pemetrexed/gemcitabine combination in pancreatic cancer | Q34810763 | ||
| Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials | Q35063516 | ||
| Irinotecan (Campto®) in the treatment of pancreatic cancer | Q35576154 | ||
| Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694) | Q36115065 | ||
| A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer | Q36612255 | ||
| Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines | Q36620291 | ||
| Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma | Q37355035 | ||
| Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity | Q38548832 | ||
| A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. | Q40459114 | ||
| FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. | Q40462713 | ||
| No standard treatment is available for advanced pancreatic cancer. | Q40466201 | ||
| Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. | Q40558393 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irinotecan | Q412197 |
| pancreatic cancer | Q212961 | ||
| P304 | page(s) | 1358-1367 | |
| P577 | publication date | 2007-04-10 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer | |
| P478 | volume | 96 |
| Q37105343 | Effect of folic acid and vitamin B12 on pemetrexed antifolate chemotherapy in nutrient lung cancer cells |
| Q38994024 | PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines |
| Q37398211 | Pancreatic cancer stem cells: fact or fiction? |
| Q37253577 | RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. |
| Q38480031 | The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models |
Search more.